Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/YbIX0KfaVgY/265651.php
Thursday, 5 September 2013
Bayer receives approval of EYLEA� for second indication in Europe
Bayer HealthCare has announced that EYLEA (aflibercept solution for injection, known in the scientific literature as VEGF Trap-Eye) has been approved by the European Commission for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). This approval marks the second indication for EYLEA in Europe, with the wet age-related macular degeneration (wAMD) indication receiving approval in December 2012...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment